-
公开(公告)号:US20240226104A1
公开(公告)日:2024-07-11
申请号:US18556250
申请日:2022-04-20
发明人: Wei Gao , Duxin Sun , Fei Wen , Ruiting Li , Hongxiang Hu , Luke F. Bugada , Yudong Song , Mahamadou Djibo
IPC分类号: A61K31/519 , A61K9/00 , A61K9/51 , A61K31/337 , A61P35/04
CPC分类号: A61K31/519 , A61K9/0019 , A61K9/5169 , A61K31/337 , A61P35/04
摘要: The present disclosure provides phosphatidylinositol 3-kinase (PI3K) inhibitors, and compositions, nanoformulations and methods for treating diseases or disorders (e.g., breast cancer, pancreatic cancer, lung cancer, and lymphoma) with PBK inhibitors or composition thereof. Disclosed herein is a composition comprising: an effective amount of a PI3K inhibitor or a pharmaceutically acceptable salt thereof; and an albumin nanoparticle.
-
公开(公告)号:US20230183282A1
公开(公告)日:2023-06-15
申请号:US17995254
申请日:2021-04-01
发明人: Duxin Sun , Wei Gao , Hongxiang Hu , Mohamed Dit Mady Traore , Yudong Song , Bo Wen , Miao He , Hebao Yuan , Ruiting Li
CPC分类号: C07H7/06 , A61P31/12 , A61K9/127 , A61K9/5169
摘要: The present invention relates to methods, compounds, and compositions for treating viral infections, including COVID-19 viral infections. In certain embodiments, the compositions comprise: i) a remdesivir analog, ii) remdesivir or a remdesivir analog, and a surfactant, a cyclodextrin, or a combination thereof, iii) nanoparticles comprising albumin and remdesivir or remdesivir analog, iv) liposomes comprising lipids and remdesivir or remdesivir analog; and/or v) microparticles comprising PLA and/or PLGA, and remdesivir or remdesivir analog. In certain embodiments, the compositions are aqueous (e.g., for intravenous administration). In other embodiments, the compositions are nebulized or in the form of a dry powder (e.g., for inhalation by an infected subject).
-
公开(公告)号:US20230025865A1
公开(公告)日:2023-01-26
申请号:US17784404
申请日:2020-12-11
发明人: Duxin Sun , Wei Gao , Hongxiang Hu
IPC分类号: C07D401/14 , A61K9/14 , A61P35/00
摘要: This disclosure provides compositions and methods for albumin nanoformulation of Bcl-2 and Bcl-xL inhibitor APG-1252 to suppress and/or inhibit growth of cancer cells (e.g., tumor cells). In particular, the present invention is directed to compositions comprising nanoparticles associated with (e.g., complexed, conjugated, encapsulated, absorbed, adsorbed, admixed) APG-1252, methods for synthesizing such nanoparticles, as well as systems and methods utilizing such nanoparticles (e.g., in diagnostic and/or therapeutic settings). Such nanoparticle formulations of APG-1252 are capable of increasing solubility, protecting against its degradation, reducing platelet toxicity, and expanding (improving) different indications to improve anticancer efficacy in various cancers and cancer metastasis in lymph nodes.
-
公开(公告)号:US20210346478A1
公开(公告)日:2021-11-11
申请号:US17232751
申请日:2021-04-16
发明人: Duxin Sun , Ryan Clauson , Hongwei Chen , Chengyi Li , Wei Gao , Luke Bugada , Fei Wen , Brett Hill , Syed Monem Rizvi
IPC分类号: A61K39/00 , A61K47/02 , A61K9/16 , A61K38/19 , A61K47/69 , A61K47/64 , A61K45/06 , A61K39/295 , A61P35/00 , A61K39/39
摘要: The present invention provides, in some embodiments, methods, compositions, systems, and kits comprising nano-satellite complexes comprising: a core nanoparticle complex comprising a biocompatible coating surrounding a nanoparticle core; 3-25 satellite particles attached to, or absorbed to, said biocompatible coating; a plurality of antigenic peptides conjugated to, or absorbed to, said satellite particles; and at least one additional property. In other embodiments, provided herein are nano-satellite complexes comprising: a core nanoparticle complex comprising a biocompatible coating surrounding a nanoparticle core; a plurality of satellite particles attached to, or absorbed to, said biocompatible coating; a plurality of antigenic peptides conjugated to, or absorbed to, said satellite particles; and a plurality of LIGHT (TNFSF14) peptides conjugated to, or absorbed to, said satellite particles. In some embodiments, administration of the nanosatellite complexes to a subject with cancer achieves long-term cancer remission (e.g., when combined with an immune checkpoint inhibitor, such as αPD1).
-
-
-